UBS Group’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

UBS Group’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-193	Closed	-$4.75K	–	11186
2026 Q1	$4.75K	Buy	+193	New	+$4.92K	﹤0.01%	8892
2025 Q4	–	Sell	-2,184	Closed	-$51.1K	–	11333
2025 Q3	$51.1K	Sell	2,184 -369	-14%	-$8.48K	﹤0.01%	7546
2025 Q2	$58K	Buy	2,553 +1,955	+327%	+$42.4K	﹤0.01%	7659
2025 Q1	$12.9K	Buy	598 +152	+34%	+$3.46K	﹤0.01%	8477
2024 Q4	$10.1K	Buy	446 +224	+101%	+$5.53K	﹤0.01%	8323
2024 Q3	$5.95K	Buy	+222	New	+$5.96K	﹤0.01%	8013

Other funds holding THNR

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $131M AUM

UBS Group's THNR Position: Q2 2026 in Review

UBS Group sold out of Amplify Weight Loss Drug & Treatment ETF (THNR) in Q2 2026, closing a stake of 193 shares — an estimated $4.75K sold.

UBS Group first reported a position in THNR in Q3 2024 and held it in 6 quarters. The position peaked at $58K in Q2 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q2 2026.

UBS Group reported no remaining Amplify Weight Loss Drug & Treatment ETF position as of Q2 2026 after selling out during the quarter.
UBS Group sold 193 Amplify Weight Loss Drug & Treatment ETF shares in Q2 2026, an estimated $4.75K.
UBS Group first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q3 2024 and held it in 6 quarters.
UBS Group's Amplify Weight Loss Drug & Treatment ETF position peaked at $58K in Q2 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.